Need for the study PART 2
Prior data on serum adiponectin levels in patients with psoriasis have not revealed any particular pattern; some studies have shown decreased levels while others have shown higher levels (268), (134), (269) . The studies so far have evaluated adiponectin levels in patients with psoriasis and normal controls. Some have studied its levels before and after therapy (263) and some its level in relation to obesity (269), (132). None of the earlier studies have analysed the adiponectin levels in relation to MetS in patients with psoriasis as well as controls which is an important confounding factor.
So far only one study has demonstrated the expression of adiponectin receptor1 in the epidermal layers. However immunohistochemistry was performed from biopsies of only 3 patients with psoriasis (288).Adiponectin receptor 2 expression has not been studied in human keratinocytes.
AIMS

Study population
The second part -the study of psoriasis and adiponectin, was an investigational study which sought to record the variations in serum adiponectin and adiponectin receptors between the psoriatics and the normal population. We recruited further sixty patients with psoriasis from Sri Ramachandra out patient clinic.
Aim PART 2A
To correlate the serum adiponectin levels in psoriatic patients with and without MetS and in controls with and without MetS.
To correlate the serum insulin levels in psoriatic patients with and without MetS and in controls with and without MetS.
To compare serum adiponectin levels and serum insulin levels between psoriatics and controls with and without MetS.
PART 2B
To identify the presence of adiponectin receptors in human keratinocytes.
To trace the pattern of adiponectin receptor expression in psoriatic patients with and without MetS. To correlate the serum adiponectin level with adiponectin receptor expression between patients with psoriasis and controls.
MATERIALS & METHODS
Methods
PART 2A CIRCULATING ADIPONECTIN LEVELS IN INDIAN PATIENTS WITH PSORIASIS AND ITS RELATION TO METABOLIC SYNDROME:
Study population
We recruited further sixty patients with psoriasis and 40 controls with other non inflammatory skin diseases were included from Sri Ramachandra University psoriasis out patient clinic. The 60 patients with psoriasis were recruited over a period of 6 months from August 2011 to February 2012. All 100 patients gave informed consent. The sixty patients who had plaque type of psoriasis were more than 18 years. They were grouped into two. 31 patients with plaque type psoriasis without MetS or any other metabolic co morbidities like diabetes, dyslipidemia, obesity or hypertension were included. The other group of 29 patients with psoriasis had MetS. All patients receiving systemic therapy or those who had received any systemic drug in the last 6 weeks were excluded from the study. 40 patients who attended the skin department for other skin ailments were the controls, 20 of whom had MetS and 20 without MetS or any other metabolic co morbidity.
All patients and controls underwent the following laboratory tests at Sri Ramachandra Central Diagnostic Laboratory after overnight fasting. Serum glucose levels was measured by the hexokinase method, lipid profile which included total cholesterol, low density lipoprotein, high density lipoprotein and triglyceride levels was assessed by enzymatic methods. Serum insulin levels were measured using AXSYM auto analyser (ABBOTT laboratory, IL, USA; CV 4-6%). Insulin resistance was estimated by HOMA-IR, calculated as follows; fasting serum insulin (µU/ml) X fasting plasma glucose (mg/dl)/405 (270).
Assay for serum adiponectin
Blood samples were collected from both patients and controls after overnight fasting in tubes without anticoagulant and centrifuged to obtain serum. Serum adiponectin was measured using enzyme linked immune assay (Human adiponectin; Orgenium Laboratories Business Unit, Tiilitie 3, Finland)).
All reagents and samples were brought to room temperature.
Dilution of test standard:
The lyophilised adiponectin standard was diluted with sample diluents. 125 µl of adiponectin standard was added to 125 µl of sample diluents in the first tube to obtain 15ng/ml of adiponectin standard.
200µl of dilution buffer was added to other 4 wells and 3 fold serial dilutions in dilution tubes was performed as shown in the figure below.. To tube number 6 only sample diluent was added as a blank. 15ng/ml 5ng/ml 1.67ng/ml 0.56ng/ml 0.185ng/ml 0ng/ml
Sample preparation and dilution:
Sample diluent was used for dilution of all serum samples. Serum samples were diluted to 1:1000 with the sample diluent. The dilution was done in two steps. First we diluted 1:100 (5µl sample +495µl sample diluent), and further 1:10 (100µl diluted sample +900µl sample diluent).
Test procedure:
Step 1 50µl of each diluted serum, diluted standards (starting from 15ng/ml) and sample diluent as a blank was added into the appropriate wells of the strips. This was incubated for 1 hour at room temperature and washed 5 times with1 X wash solution (300µl each).
50µl of green coloured biotinylated detection antibody was added to all wells containing standards and samples. This was again incubated for 1 hour and washed 5 times with1 X wash solution (300µl each).
Step 2 50 µl of streptavidin -HRP solution was added to each well and incubated for 30 minutes at room temperature. This was washed 5 times with1 X wash solution (300µl each).
Step 3 50 µl of TMB substrate was added to each well. This was incubated for 20 minutes at room temperature in the dark.
Step4
25 µl of stop solution was added to each well. Reading was done at 450nm immediately.
Step 5
Results were calculated. The standard curve was generated by plotting the average optical density (450nm) obtained for each of the standard concentrations on the Y axis versus the corresponding adiponectin concentration (ng/ml) on the X axis. The serum value was multiplied by the dilution factor (1000).
PART 2B ADIPONECTIN RECEPTOR EXPRESSION IN KERATINOCYTES OF PATIENTS WITH PSORIASIS WITH AND WITHOUT
METABOLIC SYNDROME
Study population:
From the 60 patients for whom serum adiponectin was measured twenty patients were recruited into the study. The inclusion criteria were age more than 18 years and clinical diagnosis of plaque type psoriasis. Of these twenty patients 9 patients with psoriasis (age group of 34 -65 years) had MetS and 11 patients (age group of 29-67 years) who did not have MetS or any other metabolic co morbidity like diabetes, hypertension, dyslipidemia or obesity were included. Patients on current treatment and those who received cyclosporine, acitretin, psoralens and methotrexate within the last 6 weeks were excluded from the study. Three normal controls were included from the surgery outpatients who were posted for other surgeries after informed consent. This study was conducted in accordance with the principles of the Declaration of Helsinki.
Skin biopsies:
Spindle-shaped biopsies were taken with informed consent from all twenty patients with psoriasis under aseptic precautions. Biopsies were taken from both the psoriasis patch and normal skin away from the site of affection from those who consented for both. Some patients consented only from the lesion. Schematic representation of number of patients with and without MetS and the number of those who consented for biopsies from both (normal skin and psoriatic patch) or only one site is given in figure below.
Flow chart showing number of samples obtained from patients with psoriasis:
Processing of tissue:
Skin biopsy samples were immediately fixed in 10% phosphate buffered formalin for 24
hours. The tissue was submitted for processing through automated tissue processor.
Paraffin sections of 5 m thickness were made and mounted on glass slides. Hematoxylin and eosin staining was done to study the histopathological features. Sections were examined under high power (40X) field to observe for immunoreactivity.
Immediately before use, vials were reconstituted with 50 l of distilled water and the solution obtained was further diluted to 1:200 for usage in tissue sections.
Immunohistochemistry:
For immunohistochemistry 5µ thick sections were mounted on 0.1% poly -L-lysine coated slides and placed in slide warmer at 60 degree centigrade temperature for 30 minutes.
Then transferred to xylene,2 changes 5 minutes each for deparafinisation, followed by two changes of absolute alcohol and one change in 70% alcohol for one minute each. After rinsing gently in running water the slides were placed in the 0.01 M citrate buffer pH 6.0 for pressure cooker heating (pressure cooker with an operating pressure of about 103kpa/115 that ensured a temperature of about 120 degree centigrade at full pressure).
Sections were left in the target retrieval buffer at room temperature for 20 minutes in the pressure cooker. After boiling, the pressure cooker was cooled by transferring it to a sink with cold running water; distilled water wash of slide was done and transferred to Tris (Tris hydroxyl methyl amino methane pH7.6) buffer solution for 5 minutes. Endogenous peroxidase block with 2% normal goat serum was done and rinsed with distilled water and
Tris buffer solution and power block was added for 10 minutes. The slides were then incubated with primary antibody for 1 hour and rinsed again in Tris buffer solution.
Positive Control tissue used were adipo R1: human myocardium and adipo R2: human liver. After primary Tris buffer wash, super enhancer was added for 20 minutes followed by Tris buffer wash, to which polymer HRP was added and incubated for half hour. Tris buffer wash was repeated. DAB chromogen (3'3 di-amino benzidine) was added for 10 minutes followed by distilled water wash and counter stained with hematoxylin for secondary antibodies.
Semi quantitative measurements & expression pattern:
The intensities of adipo R1 and adipo R2 were graded from faint to 3+ as given below. 
STATISTICAL ANALYSIS
Statistical Analysis
Analysis was carried out using SPSS (Statistical Package for social studies), South Asia 
Results
Characteristics of the study population (table 4.1)
The demographic data of both patients with psoriasis and controls are summarized in table 4.1 and figure4.3. Both groups were matched for age, sex and BMI. Those who consumed alcohol were significantly more in the psoriasis group. Hypertension was common among patients with psoriasis. Only one patient with psoriasis had coronary artery disease. Serum insulin levels did not differ between psoriasis and controls. Mean PASI score was 5.10.
Majority of patients (86.6%) had mild psoriasis. Mean duration of the disease was 5.1 years. 28% had psoriatic arthritis. Serum adiponectin was significantly lower in patients with psoriasis (mean =7630 ng/ml) when compared to controls (mean= 10058 ng/ml).
There was a significant inverse relationship between serum insulin, HOMA-IR index and serum adiponectin (p=0.04, 0.001) Although there were no differences in the adiponectin levels between normal weight and overweight groups there was a significant decrease in adiponectin levels in obese patients when compared to normal weight patients in both groups (p=0.01). The difference between serum adiponectin between patients with psoriasis and controls persisted after adjustment for age and BMI. There was also no difference in serum adiponectin levels between males and females in both groups.
Patients with MetS in both groups had significantly higher BMI when compared to those without MetS.
There was no significant difference in the HOMA-IR values between psoriasis and controls. In patients without MetS in both groups showed significantly reduced adiponectin in patients with psoriasis without MetS when compared to controls. (Table4.3).We also found significantly lower levels of adiponectin in controls with MetS when compared to patients with psoriasis without MetS (p=0.001).
Serum adiponectin and arthritis, duration and severity of psoriasis
There was no significant association between PASI score and serum adiponectin levels as seen in figure 4.8 (correlation coefficient (T) = -0.014, p=0.873). Likewise there was no association between arthritis and the duration of psoriasis with adiponectin levels. There was also no relationship between IR and arthritis or duration of psoriasis. The demographic data of patients with psoriasis are given in table4.4a &b. The mean age of patients was 44.58 years. Mean PASI score was 6.95 and 7(29.2%) had psoriatic arthritis. Serum adiponectin levels were lower in patients with psoriasis than in controls but not significantly lower. Among the 14 patients who had metabolic syndrome 9(37%)
were diabetic and 7(29.2%) had hypertension. All 24 skin samples taken from psoriasis lesions showed histopathological features consistent with psoriasis. Off the six samples from the uninvolved skin of patients with psoriasis 4 had histopathological features of psoriasis such as parakeratosis, elongation of rete ridges. 
Table4.4a: General Characteristics of patients with psoriasis and Metabolic syndrome (odds ratio)
Expression of Adipo R1 & AdipoR2 in the epidermis of controls
AdipoR1 and adipoR2 were expressed from the basal layer through the stratum spinosum and granular layer of the epidermis. Stratum corneum did not show any expression of adiponectin receptors. The intensity was uniformly very strong (4+) in the viable layers of the epidermis as shown in figure 4.8.
Expression of Adipo R1 & Adipo R2 in the epidermis of patients with psoriasis
Involved skin
The various patterns of expression of Adipo R1 that were seen in psoriatic lesions were Of the 6 normal skin samples of patients with psoriasis 4 showed focal loss with positivity in all layers and 2 showed complete loss. The intensities were from faint to 3+. There was also a significant difference in the pattern of expression between uninvolved skin and normal skin from controls. The intensity was also significantly reduced in normal skin of patients with psoriasis (tables 4.7& 4.8). 
Association of adiponectin receptor expression with other parameters
There was no correlation between serum adiponectin and PASI score or duration of psoriasis correlation coefficient. There was also no association between serum adiponectin levels and psoriatic arthritis. AdipoR1 and AdipoR2 intensities did show a decrease with serum adiponectin, but did not reach the level of significance (p=0.276). There was also no association of receptor expression with age, BMI, abdominal girth, serum insulin and HOMA IR with adiponectin receptor expression in the psoriatic patches. Severity of psoriasis or the presence of arthritis did not influence AdipoR1 and AdipoR2 expression.
Presence of diabetes, hypertension, obesity and dyslipidemia did not alter the adiponectin receptor expression in psoriatic lesions. In the skin adiponectin receptors have been found to be expressed in dermal fibroblasts of mouse skin and full length adiponectin increased hyaluronan production and upregulated hyaluronan synthase. AdipoR1 and AdipoR2 mRNAs were also expressed in keratinocytes but neither full length nor globular adiponectin was involved in hyaluronan synthesis. In human dermal fibroblasts it was found that adiponectin increased the phosphorylation of AMPK and that AICAR significantly up-regulated PPAR and hyaluronan synthase 2 (HAS2) gene expression. It was suggested that AMPK/PPAR pathway was involved in promoting hyaluronan synthesis. (282) While PPAR-alpha controls enzymes from the lipid and glucose metabolism in the liver, heart and muscles, it is also involved in skin homeostasis. In the skin it controls keratinocyte proliferation/differentiation, contributes to wound healing and regulates skin inflammation. The action of adiponectin on keratinocytes may also be due to its binding with adiponectin receptors on keratinocytes and consequently upregulation of AMPK/PPAR pathway. We have found a significant downregulation of adiponectin receptors in psoriatic epidermis when compared to controls. This reduction of AdipoR1/R2 probably results in decreased binding of adiponectin with its receptors and thereby reduced PPAR stimulation and hence increasing cutaneous inflammation. It follows that a down regulation of receptors must lead to an increase in the serum adiponectin levels but our study as well as earlier studies have shown reduced levels of adiponectin in patients with psoriasis. This is possibly due to the various factors like obesity, cardiovascular disease, diabetes co existing in psoriatic patients which also influence serum adiponectin levels. Thus the influence of adiponectin on adiponectin receptors in the keratinocytes is probably independent of its level and effect in the blood, liver and skeletal muscle.
T-cadherin is another molecule considered by some researchers as a third adiponectin receptor as it binds to high molecular weight adiponectin. Zhou et al found that there was down regulation of T-cadherin in keratinocytes of psoriatic skin (287).
This study was undertaken to investigate the expression of adiponectin receptors in keratinocytes of patients with psoriasis with respect to MetS. Our immunohistochemical findings have shown that both AdipoR1 and AdipoR2 are expressed in all viable layers of the epidermis in normal skin. This is consistent with a recent study in which AdipoR1 was found to be expressed in all the epidermal layers especially the basal layer in normal skin (288). However AdipoR2 expression was not studied (288). In patients with psoriasis the intensity and density of expression was significantly lower than that of normal skin. This is also concordant with the earlier study in which they have proposed that the decreased AdipoR1 in psoriatic keratinocytes may contribute to the development of the lesion by modulating cytokine response of keratinocytes (288).They found that uninvolved psoriatic skin expressed AdipoR1 in a similar pattern as normal skin of controls (288). In contrary our study showed a significant reduction in the expression of AdipoR1 and AdipoR2 in the uninvolved skin of patients with psoriasis when compared to normal skin of controls. This is probably because, out of 6 apparently normal skin samples from patients with psoriasis 4 showed histopathological features of psoriasis. Psoriasis is a state of systemic inflammation and many earlier studies have shown histopathological changes and molecular defects in the uninvolved skin of psoriasis (289) They also demonstrated that TNF and IL6 from keratinocyes are inhibited by adiponectin (288).
Serum adiponectin levels did show a decrease with the reduction of receptor expression but did not reach the level of significance. This is possibly due to the sample size being only 24.
This is the first study to our knowledge that has demonstrated both AdipoR1 and AdipoR2 in the keratinocytes of human skin and its expression in patients with psoriasis from both lesional and uninvolved skin with respect to MetS. This study further suggests the role of adiponectin at the level of the epidermis. Therefore upregulation of adiponectin receptors may be a target for therapeutic interventions in psoriasis.
